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lymph nodes and a boost volume including the prostate and 
seminal vesicles; TPs were generated in simultaneous boost 
technique. For AP, a progressive engine is used where the 
user defines prioritized optimization goals for PTV-coverage 
and dose thresholds and priorities for each organ at risk 
(OAR). The AP engine automatically creates objectives and 
required optimization aid structures (OAS), and multiple 
optimization loops iteratively reformulate and adjust the 
optimization objectives to meet the goals and further lower 
dose to OAR with minimal compromise to the target 
coverage. For manual planning, additional OAS have to be 
generated by the planner, objectives and priorities have to 
be adjusted manually for each optimization loop. For plan 
comparison, various dose and dose volume metrics (Dmed, 
D98%, D2% V95% for target volumes, D2%, Dmed and Vx% for OARs) as 
well as homogeneity index (HI = (D2%-D98%)/ D50%) and 
conformity index (CIPaddick = TV²PI/(PI*TV)) were evaluated. 
Efficiency of the plan optimization procedure was estimated 
by means of total time required to create a TP. 
Results: PTV coverage V95% was 93.5±3.5% and 97.9±1.3% and 
boost coverage was 95.5±2.0% and 98.3±1.7% for MP and AP, 
respectively. Homogeneity index for the PTV was 0.14±0.02 
and 0.12±0.02 and for the boost it was 0.11±0.02 and 
0.07±0.02 for MP and AP, respectively. CI was 13% and 16% 
higher in manual plans compared to automatic plans for PTV 
and boost, respectively. Dmed and D2% for bladder and femoral 
heads showed no particular differences between manual and 
automatic plans. However, considerable deviations in Dmed 
were found for the rectum (27.8±4.7Gy vs 33.3±5.8Gy for MP 
and AP, respectively) and intestine (25.2±7.5Gy and 
22.8±8.2Gy for MP and AP, respectively). Further, VTissue30% 
representing tissue outside the target volumes received 36% 
more dose in AP compared to MP. The time to create a 
treatment plan was <1 hour for MP and >2 hours for AP. 
Conclusions: Automatically generated TPs improve target 
coverage and homogeneity at the cost of slightly decreased 
conformity when compared to manual TPs. OAR sparing is 
mostly comparable, higher dose contribution to normal tissue 
outside the PTV was found for AP. Since higher low dose 
volume was detected in normal tissue for AP plans, each TP 
needs to be evaluated by an experienced planner and 
adapted when necessary. Prioritized optimization goals in AP 
need to be carefully established and the overall time 
required to create a plan remains to be optimized. 
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Purpose/Objective: Knowledge based planning software 
RapidPlanTM was used to develop a pre-configured planning 
model for 5-field IMRT prostate plans. Prostates were 
planned to 78 Gy, seminal vesicles to 60 Gy and an 
intermediate shell, grown from prostate, to 71 Gy. This study 
describes the steps undertaken to create, test and develop a 
model to generate clinically acceptable prostate plans. 
Materials and Methods: Preparing and optimizing a model for 
clinical use consisted of 2 stages: training the dose prediction 
algorithm using a library of approved clinical plans; and 
defining how dose predictions were used to generate patient-
specific objectives in the IMRT optimizer. Structures and dose 
distributions from previously-treated prostate patients were 
used to train the model. Sufficient plans, 41 initially, were 
added as directed by initial statistical analyses to ensure the 
model was adequately trained for all structures. Analysis of 
potential outliers was then carried out to exclude patients 
that would adversely influence the model outcome. 3 types 
of model were created: i) all plans included; ii) the most 
extreme outliers were excluded (e.g. patients with prosthetic 
hips); iii) all patients identified as outliers by RapidPlan were 
excluded. The resulting models were then used to generate 
plans for 5 patients who had not been included in the 
modelling process. Plan optimization objectives consisted of 
a line objective and maximum dose point objective for each 
OAR, and minimum and maximum point objectives for all 
PTVs. Comparisons of generated plans with corresponding 
clinical plans were carried out to indicate required changes 
to the models. Model parameters were then iteratively 
adjusted until plan quality converged with that of the clinical 
plans for the test patients.  
Results: A number of changes to the initial model were 
required. These included setting the normal tissue objectives 
from the default to those used clinically in local IMRT 
protocols while maintaining the default smoothing 
parameters set. For the final version of the model, plans 
created using the RapidPlan model were similar to the 
equivalent plans devised by experienced planners and used 
clinically (Figure 1, Table 1). In some cases PTV coverage was 
slightly reduced in the superior and inferior edges for 
RapidPlan plans compared with clinical plans. OAR doses 
were similar for both RapidPlan and clinical plans. No 
significant difference was seen between the performance of 
models i), ii) and iii).  
 
Figure 1. Comparison of RapidPlan (left) and Clinical (right) 
plan dose distributions. 
Table 1. Table comparing PTV parameters of plans generated 
using the final two RapidPlan models, v5 & v4d, which are 
versions of model ii) and the corresponding clinical plan. 
 
 
 
Conclusions: This study has highlighted the potential of the 
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RapidPlan software in generating clinically acceptable plans 
in a semi-automated manner for 5-field IMRT prostate 
treatments. Statistical guidance on exclusion of outliers 
appears somewhat conservative – inclusion of all available 
good quality plans should improve the scope and robustness 
of the model.  
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Purpose/Objective: The aim of this study is to evaluate the 
geometric performances of the treatment planning system 
(TPS) in external radiotherapy in order to identify its limits. 
Materials and Methods: Eclipse (Version 10) TPS was 
evaluated with the quality control software Digibox (version 
2.2). Digibox has a control points database, in which the 
operator selects some to create a set of control points that 
will be identified as a new quality control. For each control 
point of the quality control, Digibox prepares a digital test 
object (DTO) that automatically transfer to the TPS via the 
network. The operator then performs on the TPS the 
geometrical operation he wants to test. The test result is 
then returned to Digibox that analyses by comparing it with a 
theoretical result DTO. This study is composed of two 
sections. Section 1 deals with the beams display. Section 2 is 
about the definition of contours, margins, isocenter and the 
beams conformation. 
Results: 152 elementary geometrical operations were 
performed for a period of 14 hours of work, not included 
import and export times. The results of section 1 show no 
significant difference. The tests were: rotation of the 
collimator, beam angles, filed sizes and beam divergence. 
The results of section 2 showed however some important 
differences, especially on 3D margins for volumes with 
variable sections and small structures (<12 cm3), and the 
automatic positioning of the isocenter in complex structures. 
Minor discrepancies were identified on the conformation of 
the beams and jaws, the automatic contouring, and 
calculation of the volume of a structure showed less 
variation. 
Conclusions: Using Digibox, we could highlight two types of 
problems which one particularly concerns the stereotactic 
technique. This digital evaluation is an asset and can be used 
when an upgrade of the TPS is performed or to compare the 
performances of two TPS in the same department. Finally, 
the study of the definition of the bolus, the blocks, the 
distances calculation and the zoom tool are not yet possible 
with Digibox. 
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Purpose/Objective: To evaluate the performance of a 
knowledge-based DVH estimation constraints, namely 
RapidPlan, for optimising volumetric modulated arc therapy 
(RapidArc) applied to advanced lung cancer and to low risk 
prostate carcinoma patients.  
Materials and Methods: Two sets, one for lung and one for 
prostate cases, each of 27 previously treated patients, were 
selected to configure and train models for the estimation of 
dose-volume constraints to use in the optimization process. 
The models were subsequently validated on the same sets of 
27 plans each (closed-loop) and on further two sets each of 
25 patients not used for the training (open-loop). The two 
site groups differ mainly in the homogeneity of the 
characteristics: 
- Advanced lung cancer group: in-homogeneous dose 
prescription (50-70 Gy), wide variety of target volumes (67-
1193 cm3), two partial arc geometry 
- Low risk prostate group: homogeneous dose prescription (78 
Gy), modest variability of target volumes (80-421 cm3), single 
full arc geometry 
Analysis was based on DVH and statistics comparison between 
the RapidPlan and the original clinically accepted plans. 
Second endpoint was the evaluation of the pass-fail analysis 
for the two groups of plans based on consolidated criteria as 
following. For lung cases: D99%>95%(90%) and D1%<107% for 
CTV(PTV); mean<20Gy for ipsilateral, mean<15Gy and 
V20Gy<20% for contralateral lung; D1cm3<45Gy to spine; 
V45Gy<30% and V50Gy<20% for heart; D1cm3<70Gy and V30Gy<30% 
for oesophagus. For prostate cases: D99%>95% and D1%<107% for 
PTV; V70Gy<10%, V60Gy<40% and V50Gy<50% for rectum; V70Gy<30% 
and V60Gy<50% for bladder; Dmax<50Gy for femoral heads. 
Results: Average differences between the RapidPlan and the 
original plans of some dosimetric values are reported in the 
table (p values in parenthesis), where negative values 
indicate a superior mean plan quality of RapidPlan (the 
opposite for D99% for target). A significant improvement is 
shown for RapidPlan plans in both closed- and open-loop 
validations. 
 
 
 
In the pass-fail analysis, the rate of criteria not fulfilled was 
reduced in the lung patients group from 11% to 7% in the 
closed-loop and from 13% to 10% in the open-loop studies; in 
the prostate patients group it was reduced from 4% to 3% in 
the open-loop study. 
Conclusions: Plans were optimised using a knowledge-based 
model showed dosimetric improvements when compared to 
the original benchmark data, particularly in the sparing of 
organs at risk. The data suggests that the new engine is 
